Amplification of human papillomaviruses (HPV) is dependent on the ATM DNA damage pathway. In cells with impaired p53 activity, DNA damage repair requires the activation of p38MAPK along with MAPKAP kinase 2 (MK2). In HPV-positive cells, phosphorylation of p38 and MK2 proteins was induced along with relocalization to the cytoplasm. Treatment with MK2 or p38 inhibitors blocked HPV genome amplification, identifying the p38/MK2 pathway as a key regulator of the HPV life cycle.
, and -31 cells were generated by transfection of HFKs with recircularized HPV genomes as previously described (11, 27) , followed by selection for a cotransfected drug resistance marker. ␤-Actin was used as a loading control. The following antibodies were used: p-p38(T180/Y182, D3F9; catalog number 4511), p38(D13E1; catalog number 8690), p-MK2(T334, 27B7; catalog number 3007), and MK2 (catalog number 3042) (all from Cell Signaling Technologies, San Diego, CA). Secondary antibodies included horseradish peroxidase-linked anti-rabbit (Santa Cruz Biotechnology, Santa Cruz, CA). Levels of p-p38, p38, p-MK2, and MK2 following differentiation in high-calcium medium for 0, 48, and 96 h were determined by Western blotting. Calcium-induced differentiation was performed as described previously (27) . The 0-h data represent results for undifferentiated cells. TG (transglutaminase) was used as a differentiation marker. ␤-Actin was used as a loading control.
tigated if p38MAPK/MK2 played any role in the genome amplification of HPV-positive cells.
To determine what effect, if any, the p38/MK2 pathway plays in HPV replication, we first examined the levels and activation status of p38 and MK2 in normal and HPV-positive human keratinocytes in undifferentiated cells grown as monolayer cultures. For this analysis, the levels of p38/MK2 proteins were examined in a series of HPV-positive human keratinocyte cell lines that were generated by transfection with recircularized genomes from HPV-16, -18, and -31, as previously described (27) , as well as a biopsy sample-derived cell line that is HPV-31 positive, CIN-612. All these HPV-positive lines stably maintain episomal copies of HPV genomes in undifferentiated monolayer cultures. As shown in Fig. 1A , the levels of total p38 were similar in both HPV-positive and normal keratinocyte cells. In contrast, the phosphorylated form of p38 (p-p38) was only detected in HPV-positive cells. Slightly increased levels of total MK2 were seen in HPV-positive cells, with minimal levels of phosphorylated MK2 (p-MK2) detected in undifferentiated cultures of either normal or HPV-positive cells.
It was next important to investigate if the levels of p38/MK2 proteins were altered upon differentiation. For this analysis, we used calcium-induced differentiation, as this method allows for isolation of uniformly differentiated populations of cells (27) . Cells were seeded as monolayer cultures, followed by the addition of medium containing 1.5 mM Ca 2ϩ for 96 h (27), as previously described (11) . Extracts were harvested at the indicated times and examined by Western blotting using the corresponding antibodies. Anti-ATM (S1981, D6H9) was obtained from Cell Signaling Technologies. (B) Levels of p-p38, p38, p-MK2, and MK2 following differentiation in high-calcium medium in the presence or absence of an ATM inhibitor. Undifferentiated cells were grown as monolayer cultures in the presence or absence of 5 M ATM inhibitor KU-55933, and protein levels were determined by Western blotting. Lanes designated with Ca were induced to differentiate by the addition of high-calcium medium for 96 h with or without the presence of 5 M KU-55933, and protein levels were examined by Western blotting. (C) Levels of phosphorylated ATM and total ATM following treatment with an ATM inhibitor. (D) Levels of p-MK2 in the absence or presence of a p38 inhibitor. Cells were seeded as monolayer cultures (left) or exposed to medium containing 1.5 mM Ca 2ϩ for 96 h (right) (11) . The cells were left untreated or incubated with 10 M p-p38 inhibitor SB203580 for 96 h. Extracts were harvested and examined by Western blotting using the corresponding antibodies. TG (transglutaminase) was used as a differentiation marker. ␤-Actin was used as a loading control.
Amplification of viral genomes begins within 48 h and plateaus by 96 h after the calcium switch. In both normal and HPV-positive keratinocytes, the levels of phosphorylated p38 increased upon differentiation, while the total amounts were largely unchanged (Fig. 1B) . Slightly higher levels of MK2 total proteins were seen in HPV-positive cells and remained unchanged upon differentiation. In contrast to the minimal levels p-MK2 observed in undifferentiated HPV-positive cells, significant induction of p-MK2 was seen upon differentiation. No activation of p-MK2 was seen in either undifferentiated or differentiated normal keratinocytes (Fig. 1B) . This indicated that phosphorylation of MK2 is induced upon differentiation of HPV-positive cells.
We previously demonstrated that the ATM DNA damage pathway is constitutively activated in HPV-positive cells and that it plays a critical role in controlling amplification upon differentiation (11) . To investigate if ATM activation is linked to p38/ MK2 activation in HPV-positive cells, the levels of ATM and its phosphorylated form (p-ATM) were examined by Western blotting. Consistent with previous studies, total ATM levels were relatively unchanged between normal and HPV-positive cells, while p-ATM was detected only in HPV-positive cells (Fig. 2A) . The ATM inhibitor KU-55933 blocks phosphorylation of ATM along with its downstream targets and is specific (28) . To determine if ATM was responsible for activating phosphorylation of MK2, HPV-positive cells were induced to differentiate in high-calcium medium and treated with KU-55933, and the levels of phosphorylated MK2 were examined by Western analysis. As seen in Fig. 2B , treatment of cells with KU-55933 blocked phosphorylation of p-p38 without affecting total levels of p38. Similarly, phosphorylation of MK2 was blocked following treatment of HPV-positive cells that had been induced to differentiate (Fig. 2B) . Treatment of cells with KU-55933 also inhibited p-ATM (Fig. 2C) . This demonstrated that phosphorylation of both p38 and MK2 is dependent on ATM in HPV-positive cells. Cells were also treated with an inhibitor of p38 (Fig. 2D) , and MK2 phosphorylation was significantly reduced, demonstrating a dependence on p-p38 activity.
Neither the p38 nor MK2 inhibitors had any effect on the expression of transglutaminase, a marker of epithelial differentiation (Fig. 2C) or proliferation (data not shown) .
Upon DNA damage, the p38/MK2 complex relocalizes from the nucleus to the cytoplasm to target a series of factors, some of which regulate the stability of a number of mRNAs (18, 29) . We therefore investigated the cellular localization of p-MK2 during the differentiation of HPV-positive cells by using immunofluorescence with cells induced to differentiate in high-calcium medium. As shown in Fig. 3 , very low levels of p-MK2 were found in undifferentiated cells. Upon differentiation, we observed induction of MK2 phosphorylation and localization of p-MK2 to the cytoplasm (Fig. 3) . Similar localization was seen with p-p38, which formed a complex with p-MK2. One target of cytoplasmic p-MK2 kinase activity is the chaperone protein HSP-27 (30, 31), and we observed via Western blotting that it became phosphorylated upon differentiation of HPV-positive cells (Fig. 4) . Furthermore, the addition of MK2 inhibitors blocked phosphorylation of HSP-27 (Fig. 4) . This confirmed that p-MK2 is active in differentiated HPV-positive cells. Many of the factors described as MK2 targets, including HSP-27, contribute to cell cycle arrest in G 2 /M (32) and work in parallel with factors targeted by the nuclear DNA damage kinases CHK1 and CHK2 (19) .
Our results indicate the p38/MK2 pathway is activated upon differentiation of HPV-positive cells but not normal cells. Next, it was important to investigate if the p38/MK2 pathway had any role in the regulation of HPV replication in undifferentiated and differentiated cells. In undifferentiated HPV-positive cells, treatment with either p38 or MK2 inhibitors showed no effect on genome copy number (Fig. 5A) , indicating the p38/MK2 pathway is not involved in the stable maintenance of HPV genomes, even though ATM and p38 are activated. Upon calcium-induced differentiation, only about a quarter of cells amplify viral DNA, and the total amount of HPV DNA is increased (11) . When HPV-positive cells were differentiated in the presence of either a p38 or MK2 inhibitor, genome amplification was significantly suppressed ( and C). Similar effects were seen in multiple independent experiments. Treatment of cells with these inhibitors did not affect the phosphorylation of ATM (data not shown). These results indicated that the p38/MK2 pathway is activated in HPV-positive cells and plays an important role in the differentiation-specific genome amplification of HPV. Our studies identified a novel role of the p38/MK2 pathway in the control of HPV amplification. The p38/MK2 pathway was found to be activated in HPV-positive cells upon differentiation, and it was observed to be critical for genome amplification. MK2 is a Ser/Thr kinase that is regulated through phosphorylation by p38 MAPK and ATM. The MK2 kinase has been reported to be involved in many cellular processes, including stress and inflammatory responses (33, 34) , nuclear export (29), gene expression regulation (33, 35, 36) , and cell proliferation (37) . Recently, the p38/ MK2 pathway was identified as an alternative pathway in the DNA damage response (17) (18) (19) (20) (21) . One of the important downstream effectors of the DDR is the p53 tumor suppressor protein, whose activation can mediate cell cycle arrest to repair DNA damage or to induce apoptotic cell death (38) . In p53-deficient cells, p38/ MK2 functions as a third member of the DDR pathway (21) . In our studies, we determined that MK2 phosphorylation is specifically induced upon differentiation of HPV-positive cells. As such, it is one of only three DNA damage factors that have been identified to be induced upon differentiation. In addition to p-MK2, ␥-H2AX and p-NBS1 are two members of the ATM pathway (39) whose activation increases upon differentiation; this contrasts with ATM and CHK2, which are activated in both differentiated and undifferentiated cells (11) . Since the DDR has no role in stable or transient HPV replication but only affects differentiation-dependent genome amplification, MK2 along with ␥-H2Ax and NBS1 are likely to be critical regulators of this process.
The MK2 pathway activates the genome amplification of HPV but not stable maintenance replication, which is consistent with our observation that active MK2 kinases are only detected upon differentiation. MK2 has a broad range of downstream effectors and is involved in various cellular events. Cytoplasmic MK2 activity is critical for checkpoint maintenance, and it acts in part by stabilizing a number of mRNAs (5), so it is possible that MK2 plays a role in regulating the stabilities of a subset of viral transcripts. MK2 also phosphorylates several transcriptional factors, such as SRF and CREB (40) , whose function might be critical for regulating the late viral promoter. One known target of p-MK2 is the heat shock protein HSP27 (30, 31) , and in our studies we observed phosphorylation of HSP27 upon differentiation of HPV-positive cells that was dependent upon p-MK2 action. What role HSP27 plays in the HPV life cycle will be a focus of future studies. Finally, MK2 appears to act in parallel to CHK1 and CHK2 to activate DNA repair factors that are necessary for HPV genome amplification. Given the different cellular localizations of MK2 and CHK1/CHK2, these kinases seem to act coordinately to induce the full spectrum of DNA damage factors. Cell lysates of HPV-16, HPV-18, HPV-31, and CIN 612 cells were induced to differentiate in high-calcium medium, and levels of p-HSP27 as well as total HSP-27 were examined by Western blotting. Cells were treated with 10 M MK2 inhibitor (MK2 inhibitor III), and loss of p-HSP27 was observed. Antibodies used were anti-p-HSP-27 and anti-HSP27 (both from Cell Signaling Technologies). TG (transglutaminase) was used as a differentiation marker. ␤-Actin was used as a loading control. 
